
At KBP we are consistently reminded that patient care is the end goal of what we do daily.
Our discovery team is highly experienced in identifying new compounds with potential. The close interactions of the discovery and development teams result in a deep pipeline with multiple clinical and pre-clinical compounds.
The major organ research group is focused on the maintenance and postponement of disease progression of three primary organ systems – lung, heart, and kidney – and is capable of assessing a drug’s activity and active mechanism in both in vitro and in vivo models.
The antimicrobial group, leverages a proprietary microbial bank comprised of 20,000+ clinically-isolated strains, including anaerobic bacteria and fungi, to evaluate internally generated drug candidates effectively.
The immunology group conducts research on the roles of T- and B-cells in rheumatoid arthritis, hyperuricemia, idiopathic pulmonary fibrosis, among others.
Our laser-focus on these three therapeutic areas provides powerful and unique insights on the underlying physiological and pathological processes that drive disease, opening up new avenues to tackle specific targets. Our researchers use their expertise to locate these new directions and exploit them, resulting in innovative therapies for a wide variety of illnesses.
Our discovery team is highly experienced in identifying new compounds with potential. The close interactions of the discovery and development teams result in a deep pipeline with multiple clinical and pre-clinical compounds.
The major organ research group is focused on the maintenance and postponement of disease progression of three primary organ systems – lung, heart, and kidney – and is capable of assessing a drug’s activity and active mechanism in both in vitro and in vivo models.
The antimicrobial group, leverages a proprietary microbial bank comprised of 20,000+ clinically-isolated strains, including anaerobic bacteria and fungi, to evaluate internally generated drug candidates effectively.
The immunology group conducts research on the roles of T- and B-cells in rheumatoid arthritis, hyperuricemia, idiopathic pulmonary fibrosis, among others.
Our laser-focus on these three therapeutic areas provides powerful and unique insights on the underlying physiological and pathological processes that drive disease, opening up new avenues to tackle specific targets. Our researchers use their expertise to locate these new directions and exploit them, resulting in innovative therapies for a wide variety of illnesses.
Location: United States, New Jersey
Employees: 51-200
Total raised: $76M
Founded date: 2007
Investors 1
Date | Name | Website |
- | Bay City C... | baycitycap... |
Funding Rounds 1
Date | Series | Amount | Investors |
08.01.2018 | Series A | $76M | - |
Mentions in press and media 8
Date | Title | Description |
28.02.2025 | KBP to Contest Injunction Obtained by Novo Nordisk | SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC"), which granted an injuncti... |
18.04.2023 | Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease | PRINCETON, N.J., April 18, 2023 /PRNewswire/ -- EMJ Nephrology interviewed two World-renowned experts in nephrology and cardiology, George Bakris and Faiez Zannad, regarding the challenges of treating uncontrolled hypertension (uHTN) in pat... |
06.01.2023 | Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD | Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company de... |
08.01.2018 | China: KBP Biosciences secures $76m Series A, launches global HQ in US | Premium China’s research-focussed biotech company KBP Biosciences has closed a $76 million Series A financing co-led by Advantech Capital and SDIC Venture Capital. Continue reading this story with a subscription to DealStreetAsia. Subscribe... |
07.01.2018 | KBP Biosciences Raises $76 Million Series A | JINAN, China & PHILADELPHIA--(BUSINESS WIRE)--KBP Biosciences, a private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet medical need, today ann... |
05.01.2018 | China’s KBP gains GlaxoSmithKline executive as chief, an American headquarters and a cash boost W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | KBP Biosciences has raised $76 million as it eyes a new headquarters in the U.S. and a new chief executive in the form of ex-GlaxoSmithKline veteran Brian McVeigh. Sponsored by Agilent Technologies How would you like to win free bench space... |
05.01.2018 | China’s KBP gains GlaxoSmithKline executive as chief, an American headquarters and a cash boost | KBP Biosciences has raised $76 million as it eyes a new headquarters in the U.S. and a new chief executive in the form of ex-GlaxoSmithKline veteran Brian McVeigh. The biotech, founded by Dr. Zhen Hua Huang in Jinan, China, is looking to br... |
05.01.2018 | KBP Biosciences Raises $76M in Series A Financing | KBP Biosciences, a Greater Philadelphia Area and Jinan, China-based private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet medical need, closed a $... |